University Hospital Basel
Basel, 4031, Switzerland
Location status: Recruiting
NCT Number: NCT07321665
This prospective observational study aims to investigate the association between physical activity and clinical pregnancy rates in women undergoing medically assisted reproduction. Additionally, it evaluates how cardiorespiratory fitness, cardiovascular health, psychosocial factors, sleep quality, stress, and cognitive function relate to reproductive outcomes.
Interested in participating?
Request Info18 year–43 year
Female
Observational
Basel, 4031, Switzerland
Location status: Recruiting
Infertility affects approximately 8-12% of couples of reproductive age worldwide and represents a major medical and psychosocial burden. Medically assisted reproduction (MAR), including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), is widely used to address infertility, with more than 12,000 ART cycles performed annually in Switzerland. Despite advances in reproductive medicine, cumulative live birth rates following MAR remain moderate, highlighting the need to better understand modifiable factors that may influence treatment success.
Emerging evidence suggests that general health-related factors-such as physical activity, cardiorespiratory fitness, cardiovascular health, stress, psychosocial well-being, sleep quality, and cognitive function-may play an important role in fertility and MAR outcomes. While moderate physical activity has been associated with improved clinical pregnancy and live birth rates in some studies, the current literature is inconsistent, with conflicting findings regarding the optimal level of activity. Similarly, obesity and cardiovascular risk factors are known to negatively affect fertility and ART outcomes, potentially through mechanisms such as systemic inflammation, insulin resistance, and impaired ovarian responsiveness. Retinal microvascular markers have emerged as early indicators of cardiovascular risk and may provide additional insights into pregnancy-related complications.
Psychological stress, depression, poor sleep quality, and altered psychosocial health are prevalent among women experiencing infertility and may adversely affect reproductive physiology and treatment outcomes. Cognitive and psychosocial factors may further influence fertility indirectly through behavioral, hormonal, and lifestyle pathways. However, these domains are rarely assessed in an integrated and longitudinal manner in women undergoing MAR.
The primary objective of this exploratory, prospective, longitudinal observational study is to examine the association between physical activity and clinical pregnancy rate following MAR in biological women experiencing infertility. Secondary objectives include assessing the relationship of cardiorespiratory fitness, body mass index, blood pressure, retinal microvascular health, psychosocial health, perceived stress, sleep quality, and cognitive function with clinical pregnancy outcomes. Additional objectives are to evaluate short-term changes in physical activity, stress, psychosocial health, sleep, and cognition during hormonal stimulation, as well as changes in retinal microvascular health after completion of the first trimester in cases of pregnancy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants undergo a comprehensive, non-interventional longitudinal assessment of physical activity, cardiovascular health, psychosocial factors, sleep quality, and cognitive function integrated into routine medically assisted reproduction care.
Time frame: During the 4 year observational period
Impact of Physical activity (PA) on clinical pregnancy rate (CPR) following medically assisted reproduction (MAR)
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Physical activity and inactivity over the past seven days will be assessed using the International Physical Activity Questionnaire (IPAQ).
Furthermore activity is measured by accelerometer before and during hormonal stimulation.
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Psychological stress will be assessed using the Perceived Stress Scale.
The PSS uses a 5-point Likert scale (0-4) for each item, with scores calculated as follows:
Reverse Scoring: Positive items (e.g., PSS-10: items 4, 5, 7, 8) are reverse-scored (0 = 4, 1 = 3, 2 = 2, 3 = 1, 4 = 0).
Total Score: Sum all item scores after reversing positive items. PSS-10: Range 0-40
Interpretation: Higher scores indicate greater perceived stress. General guidelines (not diagnostic) include:
PSS-10: 0-13 (low), 14-26 (moderate), 27-40 (high)
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Depressive symptoms will be assessed using the Patient Health Questionnaires-9 (PHQ-9).
Scoring: Each question is scored 0 (not at all) to 3 (nearly every day), with a total score up to 27.
Severity Levels:
0-4: Minimal depression 5-9: Mild 10-14: Moderate 15-19: Moderately severe 20-27: Severe.
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 questionnaire (GAD-7).
Each answer is 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day).
Total Score (0-21): Sum of all 7 items.
Severity Levels:
0-4: Minimal anxiety. 5-9: Mild anxiety. 10-14: Moderate anxiety. 15-21: Severe anxiety.
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Body image will be assessed using the Body Appreciation Scale-2 (BAS-2). Body Appreciation Scale-2 (BAS-2) is a 10-item measure of one's acceptance, favorable opinions and respect of their own body.
Response Options:
Never - 1 Seldom - 2 Sometimes - 3 Often - 5 Always - 5
Scoring Procedures The mean of the 10 items is calculated for the total score. Higher scores indicate higher body appreciation.
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Sleep disturbances will be assessed using the Insomnia Severity Index (ISI). The Insomnia Severity Index (ISI) uses a 0-28 scale, with each of its seven items rated 0 (none) to 4 (very severe), where higher scores mean worse insomnia, categorizing results into no insomnia (0-7), subthreshold (8-14), moderate (15-21), and severe (22-28) insomnia, indicating clinical significance and potential need for treatment as scores rise
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Quality of life will be assessed using the WHO-5 Well-Being Index. The WHO-5 Well-Being Index scaling uses a 6-point Likert scale (0 to 5) for five questions about the past two weeks, summing them for a raw score (0-25), then multiplying by 4 to get a final score (0-100), where 0 is worst and 100 is best; scores below 50 suggest poor well-being and potential depression needing further checks, with a score of 28 or below often indicating depression
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Cognitive function will be tested by strooper task.
Time frame: preovulatory phase (day 5-14), during hormonal stimulation day (day 31-47), end of first trimester
Dietary habits will be screened by mini-EAT (Eating Assessment Tool). Mini-Eating Assessment Tool (Mini-EAT) is a 9-item rapid dietary screener that includes fruits/vegetables, whole grains, refined grains, fish/seafood, legumes/nuts/seeds, low-fat dairy, high-fat dairy, and sweets consumption.
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Time frame: During the 4 year observational period
Contact information is provided by the study sponsor or research team.
Christoph Hauser, Dr.
CONTACT
James Geiger, MD
CONTACT
University Hospital, Basel, Switzerland
Other
Acronym: REPRO-FIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04002414
Behavior, Female Urogenital Diseases
San Francisco, California, United States
View Trial DetailsNCT06686537
Body Weight, Female Urogenital Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05181748
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Athens, Attica, Greece
View Trial DetailsNCT03916978
Amenorrhea, Anovulatory Infertility
Athens, Greece
View Trial Details